Literature DB >> 3799206

Pharmacokinetics and clinical effects of scopolamine in caesarean section patients.

K K Pihlajamäki, J H Kanto, K M Oksman-Caldentey.   

Abstract

A new method (ELISA) was used to evaluate the pharmacokinetics of scopolamine following intravenous (0.005 mg/kg), intramuscular (0.01 mg/kg), and oropharyngeal (0.035 mg/kg) administration of the drug to pregnant patients anaesthetized for caesarean section. After intravenous (N = 4) the drug fast disappeared from the circulation with a half-life of about 5 min., and the serum levels generally were measurable up to 3 hours, mean elimination half-life was 1.85 hours. A fast absorption was found after intramuscular injection, tmax = 10 min. (N = 4), and the drug had a clinically significant oropharyngeal absorption as well, tmax was around 1 hour (N = 6). The intramuscular and oropharyngeal, but not the intravenous, administrations produced a marked postoperative sedative and amnesic effects. All three administration ways caused a significant antisecretory action.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3799206     DOI: 10.1111/j.1600-0773.1986.tb00166.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  4 in total

Review 1.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.

Authors:  L Putcha; N M Cintrón; J Tsui; J M Vanderploeg; W G Kramer
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Sublingually administered scopolamine for nausea in terminally ill cancer patients.

Authors:  Kengo Imai; Masayuki Ikenaga; Tomoyuki Kodama; Seitetsu Kanemura; Keiko Tamura; Tatsuya Morita
Journal:  Support Care Cancer       Date:  2013-05-31       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.